TNGX
Tango TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful positive clinical readouts and/or a strategic partnership/acquisition drive re-rating toward the high end of analyst dispersion; execution accelerates revenue pathway and reduces binary risk.
Posture
Defensive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bullish as of 2026-06-01.
What can break
Analyst downgrades or consensus target cuts
Momentum
76
Value
41
Sentiment
21
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $15.50 · Bull $26.88 · Bear $10.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $15.67
Why
Momentum76 · Δ7d -3.3
Value41 · Δ7d +0.1
Sentiment21 · Δ7d -7.3
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
76
34% active weight
Current posture
7d trendImproving
Δ7d
-3.3
Δ21d
-21.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
21
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
+7.0
Why this grade
Composite grade D. Momentum 76.2 / Value 41.1 / Sentiment 20.8
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$3.18B
Beta
1.75
Shares Out
134.59M
P/E (TTM) · Derived
-19.9
P/S (TTM)
18.03
P/FCF (TTM) · Derived
-18.05
Rev YoY
+363.6%
EPS YoY
+150.2%
Gross Margin
-
Op Margin
-165.9%
Net Debt
-$257.92M
Current Ratio
8.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology